MA55720A - Polythérapie pour le traitement d'une infection par le virus de l'hépatite b - Google Patents
Polythérapie pour le traitement d'une infection par le virus de l'hépatite bInfo
- Publication number
- MA55720A MA55720A MA055720A MA55720A MA55720A MA 55720 A MA55720 A MA 55720A MA 055720 A MA055720 A MA 055720A MA 55720 A MA55720 A MA 55720A MA 55720 A MA55720 A MA 55720A
- Authority
- MA
- Morocco
- Prior art keywords
- hepatitis
- treatment
- virus infection
- multiple therapy
- therapy
- Prior art date
Links
- 208000002672 hepatitis B Diseases 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962836066P | 2019-04-18 | 2019-04-18 | |
| US201962852749P | 2019-05-24 | 2019-05-24 | |
| US2019046036 | 2019-08-09 | ||
| US201962932346P | 2019-11-07 | 2019-11-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA55720A true MA55720A (fr) | 2022-02-23 |
Family
ID=70483181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055720A MA55720A (fr) | 2019-04-18 | 2020-04-17 | Polythérapie pour le traitement d'une infection par le virus de l'hépatite b |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20200330499A1 (fr) |
| EP (1) | EP3955917A1 (fr) |
| CN (1) | CN114072142A (fr) |
| AU (1) | AU2020259482A1 (fr) |
| CA (1) | CA3132170A1 (fr) |
| MA (1) | MA55720A (fr) |
| TW (1) | TW202103698A (fr) |
| WO (1) | WO2020214976A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202007097QA (en) * | 2018-03-14 | 2020-08-28 | Janssen Sciences Ireland Unlimited Co | Capsid assembly modulator dosing regimen |
| WO2021178612A1 (fr) * | 2020-03-05 | 2021-09-10 | Janssen Pharmaceuticals, Inc. | Polythérapie pour le traitement d'une infection par le virus de l'hépatite b |
| WO2022078479A1 (fr) * | 2020-10-16 | 2022-04-21 | Janssen Pharmaceuticals, Inc. | Polythérapie pour le traitement d'une infection par le virus de l'hépatite b |
| WO2022152869A1 (fr) * | 2021-01-15 | 2022-07-21 | Janssen Sciences Ireland Unlimited Company | Utilisation d'oligonucléotides pour des individus présentant une déficience hépatique |
| US20250034561A1 (en) * | 2021-02-18 | 2025-01-30 | Oneglobe Holdings Limited | Novel Compositions for Conjugating Oligonucleotides and Carbohydrates |
| CN117616121A (zh) * | 2021-07-09 | 2024-02-27 | 葛兰素史密斯克莱知识产权(第3号)有限公司 | 寡核苷酸用于具有肾脏损伤的个体的用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| WO2000053722A2 (fr) | 1999-03-10 | 2000-09-14 | Phogen Limited | Administration de substances a des cellules |
| CN101500548A (zh) | 2006-08-18 | 2009-08-05 | 弗·哈夫曼-拉罗切有限公司 | 用于体内递送多核苷酸的多缀合物 |
| PH12012501596A1 (en) | 2010-02-24 | 2017-02-03 | Arrowhead Res Corporation | Compositions for targeted delivery of sirna |
| US8501930B2 (en) | 2010-12-17 | 2013-08-06 | Arrowhead Madison Inc. | Peptide-based in vivo siRNA delivery system |
| PT2726613T (pt) | 2011-06-30 | 2018-10-26 | Arrowhead Pharmaceuticals Inc | Composições e métodos para inibição da expressão de genes do vírus da hepatite b |
| TW202126620A (zh) | 2013-05-17 | 2021-07-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | 胺磺醯基吡咯醯胺衍生物及其作為用於治療b型肝炎藥物的用途 |
| CN115957337A (zh) * | 2015-08-07 | 2023-04-14 | 箭头药业股份有限公司 | 乙型肝炎病毒感染的RNAi疗法 |
| HK1255835A1 (zh) * | 2016-01-08 | 2019-08-30 | Arbutus Biopharma Corporation | 用於治疗乙型肝炎的治疗组合物及方法 |
| WO2017181141A2 (fr) * | 2016-04-15 | 2017-10-19 | Novira Therapeutics, Inc. | Associations et méthodes comprenant un inhibiteur d'ensemble capside |
| JOP20190015A1 (ar) * | 2016-08-04 | 2019-02-04 | Arrowhead Pharmaceuticals Inc | عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب |
-
2020
- 2020-04-17 TW TW109113029A patent/TW202103698A/zh unknown
- 2020-04-17 CA CA3132170A patent/CA3132170A1/fr active Pending
- 2020-04-17 WO PCT/US2020/028802 patent/WO2020214976A1/fr not_active Ceased
- 2020-04-17 CN CN202080044730.5A patent/CN114072142A/zh active Pending
- 2020-04-17 US US16/851,689 patent/US20200330499A1/en not_active Abandoned
- 2020-04-17 EP EP20723963.3A patent/EP3955917A1/fr not_active Withdrawn
- 2020-04-17 AU AU2020259482A patent/AU2020259482A1/en not_active Abandoned
- 2020-04-17 MA MA055720A patent/MA55720A/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020214976A1 (fr) | 2020-10-22 |
| EP3955917A1 (fr) | 2022-02-23 |
| AU2020259482A1 (en) | 2021-10-14 |
| CN114072142A (zh) | 2022-02-18 |
| CA3132170A1 (fr) | 2020-10-22 |
| US20200330499A1 (en) | 2020-10-22 |
| TW202103698A (zh) | 2021-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR22C1063I2 (fr) | Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus du vih | |
| EP3490987A4 (fr) | Nouveaux agents thérapeutiques pour le traitement de l'infection par hbv. | |
| MA50278A (fr) | Méthodes pour le traitement de sujets atteints d'une infection par le virus de l'hépatite b (vhb) | |
| EP3474863A4 (fr) | Phosphoramidates pour le traitement du virus de l'hépatite b | |
| MA45539A (fr) | Dihydropyranopyrimidines pour le traitement d'infections virales | |
| MA45496A (fr) | Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b | |
| EP3621635A4 (fr) | Virus enveloppé résistant à l'inactivation du complément pour le traitement du cancer | |
| MA52661A (fr) | Utilisation d'inhibiteurs de fubp1 dans le traitement d'une infection par le virus de l'hépatite b | |
| EP4037706A4 (fr) | Compositions et méthodes de traitement d'une infection par le virus de l'hépatite b | |
| EP3484511A4 (fr) | Compositions vaccinales pour le traitement d'une infection par le virus zika | |
| MA52151A (fr) | Molécule d'acide nucléique pour la réduction de l'arnm de papd5 et de papd7 pour le traitement d'une infection par l'hépatite b | |
| EP3634431A4 (fr) | Compositions et méthodes thérapeutiques pour le traitement de l'hépatite b | |
| EP3773659A4 (fr) | Méthodes de traitement d'une infection par le virus de l'hépatite b (hbv) | |
| MA55375A (fr) | Méthodes thérapeutiques de traitement de l'hépatite b | |
| EP3370723A4 (fr) | Traitement d'une infection par le virus de l'hépatite delta | |
| EP3681508A4 (fr) | Méthode et composition pour le traitement d'une infection virale | |
| EP4301132A4 (fr) | Inhibiteur de rock2 pour le traitement d'une infection virale | |
| EP3840773A4 (fr) | Traitement d'une infection par le virus de l'hépatite delta par l'interféron lambda | |
| EP3416675A4 (fr) | Traitement de l'infection par le virus de l'hépatite delta par interféron lambda | |
| MA54522A (fr) | Composition pharmaceutique pour le traitement de l'hypertension artérielle pulmonaire | |
| EP3861131A4 (fr) | Thérapie génique pour le traitement de l'acidémie propionique | |
| MA55020A (fr) | Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b | |
| EP3292202A4 (fr) | Réactifs pour le traitement de l'infection par le virus de l'hépatite b (vhb) et utilisation de ceux-ci | |
| EP3752198A4 (fr) | Émetteur d'électrons thérapeutiques pour le traitement du cancer | |
| EP3430400A4 (fr) | Schémas posologiques pour le traitement d'infections fongiques |